Relmada Therapeutics, Inc.

News

Latest Press Releases, Articles & Media Resources

Press Releases

October 27, 2017
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms

Additional intellectual property protection to expand international markets for a potential paradigm changing treatment for major depression NEW YORK, Oct. 27, 2017 /PRNewswire/ --┬áRelmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that IP Australia has issued a notice of… Read More ┬╗

More Press Releases

Twitter

View All Tweets